Cel-Sci Sees Rapid Enrollment For Phase III Head And Neck Cancer Trial
- •Cel-Sci is enrolling patients for its Phase III with Multikine in head and neck cancer at a much faster pace than in the past, with the aid of two prominent contract research organizations.
- •Its first US-based expansion site engages the services of a leading oncologist who specializes in head and neck cancer and whose facility has a wide international reach.
- •Assuming favorable results that show an improvement in overall survival, doctors may still remain skeptical of cancer immunotherapy, given its novelty.
- •Despite an ongoing Phase III trial with a potentially strong platform technology, safety data, and a cGMP compliant manufacturing plant, shares remain undervalued.